All In Biotech

Drug Trial Radar · NCT01583218

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Last checked: Nov 19, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,513 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,513

Actual

Start

Mar 2012

Primary completion

Dec 2015

Study completion Jan 2016

Sponsor

Lead sponsor
Portola PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 23, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.

Conditions

  • Venous Thromboembolism (VTE)

Interventions

  • BetrixabanDrug

    Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days. Enoxaparin Placebo: Once daily, 6-14 days

  • EnoxaparinDrug

    Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days. Betrixaban Placebo: once daily, 35 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT Cohort 1: Between randomization and Day 47 (max)
  2. mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT Cohort 2: Between randomization and Day 47 (max)
  3. mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT: Between randomization and Day 47 (max)
  4. Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study MedicationTime frame: Between randomization and Day 49 (max)

Locations

462 sites in 34 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Bakersfield, California

  • Site not named

    Fresno, California

  • Site not named

    La Mesa, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Modesto, California

  • Site not named

    San Diego, California

  • Site not named

    Stanford, California

  • Site not named

    Torrance, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Bay Pines, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Oak Park, Illinois

  • Site not named

    Carmel, Indiana

  • Site not named

    Davenport, Iowa

  • Site not named

    Windsor Heights, Iowa

  • Site not named

    Topeka, Kansas

  • Site not named

    Hazard, Kentucky

  • Site not named

    Annapolis, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Grand Blanc, Michigan

  • Site not named

    Royal Oak, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    Picayune, Mississippi

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Butte, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

Showing 40 of 462 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.